Trodusquemine

Drug Profile

Trodusquemine

Alternative Names: MSI-1436; Produlestan; Trodulamine

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genaera Corporation
  • Developer DepYmed; Genaera Corporation; North Shore-Long Island Jewish Health System
  • Class Anorectics; Antihyperglycaemics; Antivirals; Biogenic amines; Cholestanes; Obesity therapies; Polyamines
  • Mechanism of Action Adrenergic uptake inhibitors; Apoptosis stimulants; Dopamine uptake inhibitors; Neuropeptide Y modulators; Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Discontinued Diabetes mellitus; HIV infections; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 15 Aug 2017 DepYmed suspends patient enrolment in a phase I trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA due to pending revision of treatment schedule (IV) (NCT02524951)
  • 01 Apr 2016 Phase-I clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02524951)
  • 20 Aug 2015 North Shore-Long Island Jewish Health System plans a phase I trial for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (NCT02524951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top